2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD22
  5. CD22 Inhibitor

CD22 Inhibitor

CD22 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-P99264
    Inotuzumab
    		Inhibitor
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
  • HY-P99034
    Moxetumomab
    		Inhibitor 99.77%
    Moxetumomab is an anti-CD22 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P99230
    Pinatuzumab
    		Inhibitor
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-141602
    Pinatuzumab vedotin
    		Inhibitor 98.25%
    Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
  • HY-P9959
    Inotuzumab ozogamicin
    		Inhibitor
    Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).